<DOC>
	<DOC>NCT01459575</DOC>
	<brief_summary>This is an open-label, Pilot study.The study hypothesis is that the feasibility and efficacy of a non-boosted ATV based HAART will be well as the first line treatment in a Chinese resource-limited setting.</brief_summary>
	<brief_title>Unboosted Atazanavir as Initial ART Therapy in China</brief_title>
	<detailed_description />
	<criteria>Signed written informed consent The subject should have established HIV infection more than 6 month. Qualifying plasma HIV RNA ≥ 2,000 c/mL and a CD4 cell count within 100 350 cells/mm3 ≥16 years of age Both females of childbearing potential and males must utilize effective barrier contraception other contraception in addition to barrier methods are permitted Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized. Patients who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study. Presence of a newly diagnosed HIVrelated opportunistic infection or any medical condition requiring acute therapy at the time of enrollment. History of hemophilia Proven or suspected acute hepatitis in the 30 days prior to study entry. Subjects with chronic hepatitis are eligible provided that their liver function enzymes are &lt; 3 times the upper limit of normal. Presence of cardiomyopathy. A history of arrhythmia or clinical symptoms potentially related to heart block or second / third degree heart block. Inability to tolerate oral medication Presence of a newly diagnosed HIVrelated opportunistic infection or any medical condition requiring acute therapy at the time of enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>China</keyword>
</DOC>